39 results about "Bone marrow fibrosis" patented technology

In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and / or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). In certain aspects, the disclosure provides ActRIIB antagonists for use in treating, preventing, or reducing the progression rate and / or severity of one or more complications associated with Janus kinase inhibitor therapy in a patient (e.g., anemia).

Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof.

Disclosed is a substance delivery carrier for an extracellular-matrix-producing cell in the bone marrow, which comprises a retinoid. Also disclosed is an agent for treating myelofibrosis by utilizing a substance capable of regulating the activity or proliferation of an extracellular-matrix-producing cell in the bone marrow.

The invention relates to the application of JAK-1 signaling pathway inhibitors in the preparation of drugs for treating brain injury and / or protecting brain nerves. Inhibitors of the JAK‑1 signaling pathway (one of which is Ruxolitinib, a clinical drug approved by the FDA for the treatment of myelofibrosis) exert neuroprotective effects by (but not limited to) inhibiting the process of pyroptosis. Injured patients provide new theoretical and technical means.

The invention belongs to the technical field of medicine, and relates to the use of vitamin B2 in preparing medicines for treating and preventing fibrosis diseases. The vitamin B2 is vitamin B2 or its medicinal derivatives. The fibrotic diseases include pulmonary fibrosis, liver fibrosis, renal fibrosis, cardiac fibrosis, endometrial fibrosis, eye fibrosis, pancreatic fibrosis, spleen fibroproliferative disease, myelofibrosis disease or fibrosis induced disease. The vitamin B2 can form a pharmaceutical composition with one or more pharmaceutical carriers. Vitamin B2 or its pharmaceutical composition can be used alone or in combination with other drugs. And it has the advantages of significant curative effect, less toxic and side effects and safe use in treating fibrotic diseases.

The invention discloses an application of a polypeptide and belongs to the field of biopharmaceuticals. 1. A polypeptide, characterized in that, the structural domain Pro-Arg-Cys-X-Y-Gly-Glu contained in the polypeptide, wherein X is Trp or Tyr; Y is Arg or Cys; and Arg-Gly-Ala- Asp-Arg-Ala; or the sequence after mutating any amino acid in the above domain; can treat various fibrotic diseases and conditions, including pulmonary fibrosis, liver fibrosis, bone marrow fibrosis, renal fibrosis and myocardial fibrosis , skin fibrosis and lung tissue lesions.

The use of chlorogenic acid in the manufacture of medicaments for increasing the effect of bone marrow cells. The pharmaceutical composition comprising chloroginic acid as active component. Chlorogenic acid can treat anaemia caused by many reasons, which comprise, but not to limited, blood loss anemia, hemolytic anemia, anhematopoietic anemia which include megaloblastic anemia, aregenerative anemia, and hypersplenia, as well as leucopeina, granulocytopeni and agranulocytopenia caused by many reasons, the change of macronucleus system casued by many reasons , for example, idiopathic thrombocytopenic purpura; myelofibrosis, bone marrow infection caused by many reasons.

The invention discloses a circular circRNA-016901 gene related to leukemia and a purpose thereof. Firstly, the existence of the circular circRNA-016901 gene is proved; through detecting a gene expression condition in a whole body radiation patient, the condition that the expression level of the gene is obviously raised is discovered. Marrow stromal cells transfected with an adenovirus vector of the over-expressed circular circRNA-016901 gene are compared with reference marrow stromal cells transfected with an empty vector; the conditions that the expression quantity of TGF-beta protein in the cells transfected with the adenovirus vector is obviously increased, the myelofibrosis is caused and is unfavorable for hematopoietic cell homing, self updating, proliferation and differentiation, and further the transplanting curative effect of the hematopoietic stem cells can be influenced are discovered, so that the circular circRNA-016901 gene and an expression product of the circular circRNA-016901 gene can be used as a marker for predicting the hematopoietic stem cell transplanting curative effect, and can be used as a target gene for preparing leukemia treating medicines and a medicine.